DDEL-14. SYSTEMIC THERAPY USE FOR THE TREATMENT OF MENINGIOMA: A SYSTEMATIC REVIEW

Abstract

Abstract INTRODUCTION Meningiomas are the most common primary central nervous system tumor. Many studies have investigated systemic therapy agents for treating meningiomas, but no study has systematically evaluated the various agents used while comparing outcomes. The goal of this study was to investigate the recent systemic therapy agents used to treat meningioma tumors and to compare relevant clinical outcomes such as progression-free survival and overall survival in patients with meningioma tumors receiving systemic therapy agents as part of their care.Materials and METHODS A systematic literature review was performed to investigate systemic therapy agents used to treat meningioma tumors. The PubMed database was used for this review and articles published from 7/4/2011 to 7/4/2021 were evaluated. The exclusion criteria included the following: animal and cell line studies, case reports, review articles, articles in a foreign language (other than English), as well as articles not related to meningioma or to systemic therapy agents. RESULTS 163 articles were initially evaluated. After excluding 152 articles using the exclusion criteria for our study, a total of 11 articles exploring 14 different systemic therapy agents were ultimately included and compared, mainly focusing on the two clinical outcomes of progression-free survival and overall survival. The study findings suggest that Bevacizumab may have the most promising results for reducing peri-tumoral edema and extending progression-free survival, with the highest observed progression-free survival at six months of 86% compared to lower progression-free survival for other systemic therapy agents. CONCLUSION This systematic review study evaluated systemic therapy agents used to treat meningioma tumors. Bevacizumab was found to have the most promising results overall. However, further studies are now needed to evaluate the efficacy and possible side effects of Bevacizumab amongst a larger population of patients with different meningioma tumor grades, locations, and treatment responses.